X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK pharma's Open offer: Our view - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK pharma's Open offer: Our view
Dec 17, 2013

Glaxosmithkline (GSK), the parent company of GSK Pharma made an open offer to shareholders to increase its stake in the latter. The price offered to the shareholders is Rs 3,100 per share. The parent company intends to buy 22,609,774 shares of GSK India, which is 24.33% of the total outstanding shares. This will increase the parent company's holding from the current 50.7% to 75%.

Threats and opportunities for GSK Pharma:

  • Competition and Pricing policy pinching the company's revenues: Since some time, the competition in the Indian domestic market has intensified. In addition to this, the new pricing policy had quite an adverse impact on GSK Pharma's revenues. While, the company has not indicated the exact impact of the pricing policy, the tepid performance of three quarters clearly indicates that the company has been adversely impacted by the same. GSK Pharma derives large part of its sales from three therapies viz., vitamins, anti-infectives and dermatology. The company's anti-infective drug Augmentin is one of the largest selling drugs in the country, this drug alone is expected to be impacted significantly due to the pricing policy.

    For the upcoming period, while the company's anti-infectives, and vitamins segments are expected to continue to remain under pressure, large part of growth will come from dermatology and other segments like respiratory and vaccines.

  • Low visibility of new launches from parent company: In our view, we do not expect major launches made by GSK Pharma from its parent company GSK Plc's portfolio in the near to medium term. Secondly, the company is looking to invest in a manufacturing facility in India. One should note that setting up this new facility will take time to become operational. Thus, any benefit from this cannot be expected in the near term.
What should investors do?

We believe that GSK Pharma has challenges on various fronts, and hence growth is expected to remain muted atleast for the next 2-3 years. Having said that, even if we assume a top line growth of around 15% with EBITDA margins of around 30% over the next 2 years which we believe is quite optimistic, we are of the view that at the current price, there is still not much upside left in the stock price of GSK Pharma.

Hence in our view, investors should take the advantage of the open offer and offload their holdings.

To Read the Full Story, Subscribe or Sign In


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jul 20, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - TEVA PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS